PRX and metabolic dysfunction-associated steatohepatitis: Moreover, we confirmed the effect of βCD-PRX in another mouse model of NASH, in which WT mice were fed a high-cholesterol (HC) diet for 20 wk (Boland et al., 2019), and received βCD-PRX treatment (30 mg/kg/d) during the last 6 wk (Fig. S3 A).